Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

Outpatient versus inpatient opioid detoxification: A randomized controlled trial

“…Three quarters of the patients who were successful in their detoxification attempt commenced naltrexone therapy, but only half were still taking the medication 1 month later; and only two, at the 6-month follow-up. This is consistent with previous studies of unsupervised naltrexone prescribing as a relapse prevention measure (Adi et al, 2006).…”

Factors affecting the practice of seclusion in an acute mental health service in Southland, New Zealand

“…As an antagonist, it does not provoke a biological response when it binds to the opioid receptors, but instead it blocks or dampens agonistmediated responses, blocking the euphoric effects of heroin and other opioids, helping patients to maintain abstinence from opioid drugs. 3 A number of systemic reviews and meta-analyses have examined the efficacy of naltrexone in people who are dependent on opioid drugs. These reviews have concluded that naltrexone appears to have some benefit in the management of opioid dependence; however, the heterogeneity of trials makes objective evaluation difficult.…”

“…These reviews have concluded that naltrexone appears to have some benefit in the management of opioid dependence; however, the heterogeneity of trials makes objective evaluation difficult. [3][4][5][6][7] The aim of this study was to use a retrospective casenote study to rigorously assess and identify other potential predictors for longer-term retention on naltrexone maintenance therapy. The case notes were also used to evaluate the overall rate of retention in treatment in a large UK community drug clinic.…”

Predictors for retention in treatment with a UK community-based naltrexone programme for opioid dependence

“…These reviews have concluded that naltrexone appears to have some benefit in the management of opioid dependence; however, the heterogeneity of trials makes objective evaluation difficult. [3][4][5][6][7] The aim of this study was to use a retrospective casenote study to rigorously assess and identify other potential predictors for longer-term retention on naltrexone maintenance therapy. The case notes were also used to evaluate the overall rate of retention in treatment in a large UK community drug clinic.…”